Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase-lpuj
12/18/2025
Emily Estrada
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA...
12/18/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
News
MET Exon 2 Skipping Mutation Associated With Self-Regulatory Mechanism for Advanced NSCLC
11/20/2025
Emily Estrada
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis...
11/20/2025
Oncology
News
Idylla Fusion Assay Delivers Rapid, Accurate Gene Fusion Detection in Non-Small Cell Lung Cancer
11/20/2025
Janelle Bradley
In a prospective analysis of 658 NSCLC samples, the Idylla fusion assay demonstrated high sensitivity and specificity for detecting key gene fusions, providing a rapid, automated alternative to NGS for molecular testing in lung cancer.
In a prospective analysis of 658 NSCLC samples, the Idylla fusion assay demonstrated high sensitivity and specificity for detecting key gene fusions, providing a rapid, automated alternative to NGS for molecular testing in lung cancer.
In a prospective analysis of 658...
11/20/2025
Oncology
News
Liquid Biopsy Using Cell-Free Nucleic Acids Enhances Variant Detection in Non-Small Cell Lung Cancer
11/20/2025
Janelle Bradley
In a large-scale study, cell-free nucleic acid sequencing using Ion Torrent AmpliSeq HD and Genexus systems accurately detected key variants across all disease stages in non-small cell lung cancer, demonstrating the clinical utility of liquid...
In a large-scale study, cell-free nucleic acid sequencing using Ion Torrent AmpliSeq HD and Genexus systems accurately detected key variants across all disease stages in non-small cell lung cancer, demonstrating the clinical utility of liquid...
In a large-scale study,...
11/20/2025
Oncology
FDA Approval
FDA Grants Accelerated Approval to Sevabertinib for HER2-Mutated Non-Squamous NSCLC
11/19/2025
Emily Estrada
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated...
11/19/2025
Oncology
News
CTNNB1 Co-Mutations Linked to Stronger Osimertinib Response in EGFR-Mutated Non-Small Cell Lung Cancer
11/19/2025
Janelle Bradley
In EGFR-mutated non-small cell lung cancer, patients with CTNNB1 co-mutations showed 100% complete response to osimertinib, while those with TP53 co-mutations had poorer outcomes and higher PD-L1 expression, underscoring the prognostic value...
In EGFR-mutated non-small cell lung cancer, patients with CTNNB1 co-mutations showed 100% complete response to osimertinib, while those with TP53 co-mutations had poorer outcomes and higher PD-L1 expression, underscoring the prognostic value...
In EGFR-mutated non-small cell...
11/19/2025
Oncology
News
Ivonescimab Plus Chemotherapy as a Potential New Standard of Care for Advanced Squamous Non-Small Cell Lung Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 HARMONi-6 trial reveal treatment with ivonescimab plus chemotherapy yielded significantly improved survival outcomes vs tislelizumab plus chemotherapy in advanced or metastatic squamous non-small cell lung cancer.
Results from the phase 3 HARMONi-6 trial reveal treatment with ivonescimab plus chemotherapy yielded significantly improved survival outcomes vs tislelizumab plus chemotherapy in advanced or metastatic squamous non-small cell lung cancer.
Results from the phase 3...
10/19/2025
Oncology

News

News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase-lpuj
12/18/2025
Emily Estrada
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA...
12/18/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
News
MET Exon 2 Skipping Mutation Associated With Self-Regulatory Mechanism for Advanced NSCLC
11/20/2025
Emily Estrada
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis...
11/20/2025
Oncology
News
Idylla Fusion Assay Delivers Rapid, Accurate Gene Fusion Detection in Non-Small Cell Lung Cancer
11/20/2025
Janelle Bradley
In a prospective analysis of 658 NSCLC samples, the Idylla fusion assay demonstrated high sensitivity and specificity for detecting key gene fusions, providing a rapid, automated alternative to NGS for molecular testing in lung cancer.
In a prospective analysis of 658 NSCLC samples, the Idylla fusion assay demonstrated high sensitivity and specificity for detecting key gene fusions, providing a rapid, automated alternative to NGS for molecular testing in lung cancer.
In a prospective analysis of 658...
11/20/2025
Oncology
News
Liquid Biopsy Using Cell-Free Nucleic Acids Enhances Variant Detection in Non-Small Cell Lung Cancer
11/20/2025
Janelle Bradley
In a large-scale study, cell-free nucleic acid sequencing using Ion Torrent AmpliSeq HD and Genexus systems accurately detected key variants across all disease stages in non-small cell lung cancer, demonstrating the clinical utility of liquid...
In a large-scale study, cell-free nucleic acid sequencing using Ion Torrent AmpliSeq HD and Genexus systems accurately detected key variants across all disease stages in non-small cell lung cancer, demonstrating the clinical utility of liquid...
In a large-scale study,...
11/20/2025
Oncology
FDA Approval
FDA Grants Accelerated Approval to Sevabertinib for HER2-Mutated Non-Squamous NSCLC
11/19/2025
Emily Estrada
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated...
11/19/2025
Oncology
News
CTNNB1 Co-Mutations Linked to Stronger Osimertinib Response in EGFR-Mutated Non-Small Cell Lung Cancer
11/19/2025
Janelle Bradley
In EGFR-mutated non-small cell lung cancer, patients with CTNNB1 co-mutations showed 100% complete response to osimertinib, while those with TP53 co-mutations had poorer outcomes and higher PD-L1 expression, underscoring the prognostic value...
In EGFR-mutated non-small cell lung cancer, patients with CTNNB1 co-mutations showed 100% complete response to osimertinib, while those with TP53 co-mutations had poorer outcomes and higher PD-L1 expression, underscoring the prognostic value...
In EGFR-mutated non-small cell...
11/19/2025
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase-lpuj
12/18/2025
Emily Estrada
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA...
12/18/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
News
MET Exon 2 Skipping Mutation Associated With Self-Regulatory Mechanism for Advanced NSCLC
11/20/2025
Emily Estrada
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis...
11/20/2025
Oncology
News
Idylla Fusion Assay Delivers Rapid, Accurate Gene Fusion Detection in Non-Small Cell Lung Cancer
11/20/2025
Janelle Bradley
In a prospective analysis of 658 NSCLC samples, the Idylla fusion assay demonstrated high sensitivity and specificity for detecting key gene fusions, providing a rapid, automated alternative to NGS for molecular testing in lung cancer.
In a prospective analysis of 658 NSCLC samples, the Idylla fusion assay demonstrated high sensitivity and specificity for detecting key gene fusions, providing a rapid, automated alternative to NGS for molecular testing in lung cancer.
In a prospective analysis of 658...
11/20/2025
Oncology
News
Liquid Biopsy Using Cell-Free Nucleic Acids Enhances Variant Detection in Non-Small Cell Lung Cancer
11/20/2025
Janelle Bradley
In a large-scale study, cell-free nucleic acid sequencing using Ion Torrent AmpliSeq HD and Genexus systems accurately detected key variants across all disease stages in non-small cell lung cancer, demonstrating the clinical utility of liquid...
In a large-scale study, cell-free nucleic acid sequencing using Ion Torrent AmpliSeq HD and Genexus systems accurately detected key variants across all disease stages in non-small cell lung cancer, demonstrating the clinical utility of liquid...
In a large-scale study,...
11/20/2025
Oncology
FDA Approval
FDA Grants Accelerated Approval to Sevabertinib for HER2-Mutated Non-Squamous NSCLC
11/19/2025
Emily Estrada
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated...
11/19/2025
Oncology
News
Ivonescimab Plus Chemotherapy as a Potential New Standard of Care for Advanced Squamous Non-Small Cell Lung Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 HARMONi-6 trial reveal treatment with ivonescimab plus chemotherapy yielded significantly improved survival outcomes vs tislelizumab plus chemotherapy in advanced or metastatic squamous non-small cell lung cancer.
Results from the phase 3 HARMONi-6 trial reveal treatment with ivonescimab plus chemotherapy yielded significantly improved survival outcomes vs tislelizumab plus chemotherapy in advanced or metastatic squamous non-small cell lung cancer.
Results from the phase 3...
10/19/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use